Sterile product development company InnoPharma has introduced acamprosate calcium, 333mg delayed-release tablets, the generic version of Campral.
The generic formulation of acamprosate delayed-release tablets was developed by InnoPharma, which entered into an agreement with Glenmark Pharmaceuticals to sell, market and distribute acamprosate in the US.
The generic product is indicated for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation.
Marketed in the US by Forest Laboratories, Campral is a registered trademark owned by Merck Sante, Lipha, Lyonnaise Industrielle Pharmaceutique.
Source:
http://drugdiscovery.pharmaceutical-business-review.com/news/innopharma-introduces-generic-version-of-campral-160813
